🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07378852
Starting soon Observational

Integrated Study on Gut Microbiota, Immune Indicators, and Trace Elements in Children With Respiratory Tract Infections

NCT07378852 · tracked via the Priya Life Science China tracker
Sponsor
Min-Tze LIONG
Phase
Observational
Started
2026-01-30
Last updated
2026-02-04

Condition(s) studied

Respiratory

Study summary

This observational study aims to investigate the characteristics of gut microbiota and their associations with immune and nutritional indicators in children with different respiratory health statuses. A total of 120 children will be enrolled and categorized into four groups: children with Mycoplasma pneumoniae pneumonia (MPP), children with acute respiratory tract infections without Mycoplasma pneumoniae (NMP), children with recurrent respiratory tract infections (RRTIs), and healthy controls. By comparing gut microbiota composition and diversity, as well as immune- and nutrition-related indicators across groups, this study seeks to clarify the potential role of intestinal dysbiosis and host immune-nutritional interactions in the pathogenesis and clinical manifestations of pediatric respiratory tract infections.

Eligibility

Sex
ALL
Min age
3 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria 1. Aged 3-14 years; 2. Good compliance and complete clinical data; 3. Guardians are informed and sign written consent; 4. MPP group: meets diagnostic criteria of Guidelines for Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children (2023 Edition); 5. NMP group: acute respiratory tract infection with negative MP-DNA/RNA; 6. RRTIs group: meets diagnostic criteria of Clinical Diagnosis and Treatment Pathway for Recurrent Respiratory Tract Infections in Children (2022 Edition); 7. Healthy controls: no respiratory infection history within the past month. Exclusion Criteria 1. Other infectious diseases (e.g., measles, pertussis, tuberculosis); 2. Congenital heart disease, immunodeficiency, or major organ dysfunction; 3. Use of antibiotics, probiotics, immunomodulators, hormones, or microecological preparations within the past 15-30 days; 4. Unqualified biological samples or incomplete laboratory data.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
The 940th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army Lanzhou Gansu
Universiti Sains Malaysia Pulau Pinang Pulau Pinang

More Min-Tze LIONG trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07378852 on ClinicalTrials.gov ↗ ← All trials in China